MCW Cancer Center logo

Funding and Grants

Current Funding Opportunities

National Cancer Institute (NCI)

 Academic-Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01) | Applications due June 5, 2015

Academic-Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01)

This Funding Opportunity Announcement (FOA) encourages applications from research partnerships formed by academic and industrial investigators to accelerate the translation of either preclinical or clinical in vivo imaging systems and/or methods that are designed to solve a targeted cancer problem. The proposed imaging system/methods may include single or multi-modality in vivo imaging and spectroscopy systems, image-guided and drug delivery systems, image analysis, and related research resources. This FOA may also include, as a secondary goal, support for other laboratory imaging or reference methods as required to validate the performance of the proposed in vivo imaging system and/or methods.

Applications due June 5, 2015

 Collaborative Research Projects to Enhance Applicability of Mouse Models for Translational Research (Collaborative R01) | Applications due June 5, 2015

Collaborative Research Projects to Enhance Applicability of Mouse Models for Translational Research (Collaborative R01)

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for collaborative R01 projects from multidisciplinary teams to expand, improve, or transform the utility of mouse cancer and tumor models for translational research. For a linked set of collaborative R01s, each site has its own Program Director(s)/Principal Investigator(s), and the program provides a mechanism for cross-site coordination and communication. Collaborative studies are appropriate to address research questions beyond the capacity of a single-site investigation, particularly to accommodate collaborations among sites with diverse expertise, perspectives, and contributions. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to $450,000 direct costs per year. Applicants may request support for up to three (3) years.

Applications due June 5, 2015

 Mechanisms of Alcohol-Associated Cancers (R01) | Applications due June 5, 2015

Mechanisms of Alcohol-Associated Cancers (R01)

This FOA issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Cancer Institute (NCI) invites applications from researchers with broad ranges of expertise to study the mechanisms by which alcohol increases cancer risk. Alcohol has been classified as carcinogenic to humans by the International Agency for Research on Cancer (IARC). Target sites for alcohol-related carcinogenesis include the oral cavity, pharynx, esophagus, larynx, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption. The goal of this program announcement is to stimulate a broad range of research into the mechanisms by which alcohol contributes to carcinogenesis.

Applications due June 5, 2015

 Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01) | Applications due June 5, 2015

Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01)

This Funding Opportunity Announcement (FOA) invites research project-cooperative agreement (U01) applications which are expected to enhance the value of quantitative imaging (QI) in clinical trials for prediction and/or measurement of response to cancer therapies. One avenue for this enhancement is to emphasize the development, optimization and validation of state-of-the-art QI methods and software tools for potential implementation in single site phase 1 or 2 clinical trials. The second avenue to enhance QI methods is to address the challenges of integrating existing and or new QI methods as required for multicenter phase 3 clinical trials. This may involve evaluation of a range of multimodal imaging approaches, harmonization of image data collection, analysis, display and clinical workflow methods across imaging platforms, or testing their performance across different cancer sites. Application Budgets for direct costs up to $500,000 per year and project duration of up to five years may be requested.

Applications due June 5, 2015

 Research Projects to Enhance Applicability of Mouse Models for Translational Research (R01) | Applications due June 5, 2015

Research Projects to Enhance Applicability of Mouse Models for Translational Research (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand and improve the utility of mouse cancer and tumor models for translational research. The NCI supports many hypothesis-driven, mechanistic R01 projects that employ mice, or develop and use mouse cancer models or human-in-mouse tumor models for many aspects of oncology research. However, the NCI has not previously supported projects devoted to ensuring that mice and mouse models used for translational research questions are appropriate for those purposes and that the models provide reliable and informative data for patient benefit. Applications to this FOA could propose to overcome limitations of mouse and human-in-mouse oncology models, define a new translational use of models or mouse genetics for unmet needs, advance standard practices for modeling human cancers and tumors in mice and for validating and credentialing models, or develop widely applicable tool strains or resources that enable cross-species comparisons. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to $450,000 direct costs per year. Applicants may request support for up to three (3) years.

Applications due June 5, 2015

 Mechanisms of Alcohol-Associated Cancers (R21) | Applications due June 16, 2015

Mechanisms of Alcohol-Associated Cancers (R21)

This FOA issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Cancer Institute (NCI) invites applications from researchers with broad ranges of expertise to study the mechanisms by which alcohol increases cancer risk. Alcohol has been classified as carcinogenic to humans by the International Agency for Research on Cancer (IARC). Target sites for alcohol-related carcinogenesis include the oral cavity, pharynx, esophagus, larynx, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption. The goal of this program announcement is to stimulate a broad range of research into the mechanisms by which alcohol contributes to carcinogenesis. The combined budget for direct costs for the two (2) year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

Applications due June 16, 2015

 Advanced Development and Validation of Emerging Technologies for Cancer-Relevant Biospecimen Science (R33) | Applications due June 17, 2015

Advanced Development and Validation of Emerging Technologies for Cancer-Relevant Biospecimen Science (R33)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing research projects on the advanced development and validation of technologies that address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and storage of cancer-relevant biospecimens. Applications must include preliminary data sufficient to justify the feasibility of the proposed technology, but may still require additional development to reach a generally useful level of functionality for cancer-related research applications. The overall goal is to support the development of highly innovative technologies capable of interrogating and/or maximizing the quality and utility of biospecimens or samples derived from those biospecimens for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to potentially accelerate and/or enhance research in cancer biology, early detection, screening, clinical diagnosis, treatment, epidemiology, and cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Applications due June 17, 2015

 Research Answers to NCI's Provocative Questions (R01) | Applications due June 29, 2015

Research Answers to NCI's Provocative Questions (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. The current issuance of the PQ Initiative involves an updated set of 12 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

Applications due June 29, 2015

 Research Answers to NCI's Provocative Questions (R21) | Applications due June 29, 2015

Research Answers to NCI's Provocative Questions (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. The current issuance of the PQ Initiative involves an updated set of 12 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

Applications due June 29, 2015

 Detection of Pathogen-Induced Cancer (DPIC) (R01) | Applications due July 10, 2015

Detection of Pathogen-Induced Cancer (DPIC) (R01)

This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), is to encourage research projects which focus on the interactions of carcinogenic pathogens with the human microbiome and the host for the detection of pathogen-induced cancer (DPIC). This FOA encourages research to assess molecular signatures associated with risk and early detection of pathogen-induced cancer and chronic inflammation associated with progression to invasive cancer.

Applications due July 10, 2015

 Imaging and Biomarkers for Early Cancer Detection (R01) | Applications due July 10, 2015

Imaging and Biomarkers for Early Cancer Detection (R01)

This Funding Opportunity Announcement (FOA) invites research project (R01) applications that combine imaging and biomarkers. The overall objective of this FOA is to facilitate collaborative imaging and biomarker research to improve cancer screening, early cancer detection and diagnosis by integrating multimodality imaging strategies and multiplexed biomarker methodologies.

Applications due July 10, 2015

Department of Defense (DOD)

 FY15 Lung Cancer Research Program (LCRP) | Pre-applications (preproposals) due June 2, 2015

FY15 Lung Cancer Research Program (LCRP)

The goal of the FY15 LCRP is to eradicate deaths from lung cancer to better the health and welfare of military Service members, Veterans, their families, and the American public. As such, the LCRP will support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer. Preproposal is required; application submission is by invitation only.

Invited Application: September 16, 2015

 Ovarian Cancer Research Program (OCRP) - Investigator-Initiated Research Award | Applications due August 2015

Ovarian Cancer Research Program (OCRP) – Investigator-Initiated Research Award

Applications to the Fiscal Year 2015 (FY15) Ovarian Cancer Research Program (OCRP) are being solicited for the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the DHA RDA Directorate manages and executes the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The executing agent for this Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP).

Foundations & Organizations

 Alliance Cancer Control Program Pilot Project Funds | Applications due June 1, 2015

Alliance Cancer Control Program Pilot Project Funds

The Alliance is pleased to announce the availability of funds to support pilot projects in the Cancer Control Program (CCP), including cancer prevention, risk assessment, screening, symptom intervention, surveillance, health outcomes research, or specific population groups, including minority and underserved, elderly, or adolescent and young adult populations. The purpose of these pilot projects is to generate preliminary data that will lead to Alliance protocols. These pilot project funds are available from the Alliance NCORP Research Base grant, which is supported by the NCI Division of Cancer Prevention (DCP). Applicants and their respective institutions must be Alliance members and must be a member of an Alliance CCP committee. You may request up to $200,000 in total costs (including institutional indirect costs). Funds cannot be used for PI (or co-investigator) salary support, or salary support for Alliance Central Office staff.

Applications must be submitted to Electra Paskett via e-mail (electra.paskett@osumc.edu) no later than June 1, 2015 (5 p.m. Eastern Time). Approved projects will be funded with an anticipated budget start date of August 1, 2015. Please note that the requested funds must be expended within one year from the date of award.

Questions about the application process should be addressed to Electra Paskett, PhD, Alliance Cancer Control Program Deputy Director at electra.paskett@osumc.edu or (614) 293-7713.

Applications due June 1, 2015

 Alliance Cancer Control Program Junior Faculty Training and Research Awards Funds | Applications due June 1, 2015

Alliance Cancer Control Program Junior Faculty Training and Research Awards Funds

The Alliance is pleased to announce the availability of funds to support training and research initiatives for junior faculty and postdoctoral fellows in the Cancer Control Program (CCP). The purpose of these awards is to facilitate ongoing training and assist junior faculty and postdocs in establishing a competitive research profile early in their career. These funds are available from the Alliance NCORP Research Base grant, which is supported by the NCI Division of Cancer Prevention (DCP).

Junior faculty may have either an instructor or assistant professor position within their institution and must be within five (5) years of their first faculty appointment, and postdoctoral fellows must maintain their fellowship for the entire one-year award period. Each applicant must work with a mentor throughout that time, allocating protected time to engage in training activities and conduct a research project in the field of cancer prevention and control, such as areas including cancer prevention, risk assessment, screening, symptom intervention, surveillance, health outcomes research, or specific population groups, including minority and underserved, elderly, or adolescent and young adult populations. Upon successful re-application, awards may be renewed for one additional year. Applicants, their mentors, and their respective institutions must be Alliance members, and either the applicant or the mentor must be a member of a relevant Alliance CCP committee. Applicants who are not current a member of an Alliance CCP committee are highly encouraged to become a member of the appropriate committee relevant to their proposal, if funded. Awardees must attend at least one Alliance Group meeting to present the results of their research.

You may request up to $200,000 in total costs (including institutional indirect costs). Funds not to exceed 10% may be requested for PI salary support; however, funds cannot be used for mentor (or co-investigator) salary support, or salary support for Alliance Central Office staff.

Note: These studies will not be considered Alliance protocols, and as such, will not have a protocol number or be eligible for cancer control credits/reimbursements or per-case payments.

Applications must be submitted to Electra Paskett via e-mail (electra.paskett@osumc.edu) no later than June 1, 2015 (5 p.m. Eastern Time). Approved projects will be funded with an anticipated budget start date of August 1, 2015. Please note that the requested funds must be expended within one year from the date of award.

Questions about the application process should be addressed to Electra Paskett, PhD, Alliance Cancer Control Program Deputy Director, at electra.paskett@osumc.edu or (614) 293-7713.

Applications due June 1, 2015

 Alliance for Clinical Trials in Oncology Foundation: 2016 Alliance Scholar Awards | Applications due June 15, 2015

Alliance for Clinical Trials in Oncology Foundation: 2016 Alliance Scholar Awards

Alliance Scholar Award applicants must be oncology junior faculty at Alliance institutions within five (5) years of training (rank below Associate Professor), who have completed training in an oncology clinical specialty (e.g., medical, surgical, radiation, gynecologic, etc.). Additionally, proposals must include a letter of support from the appropriate Alliance Scientific Committee Chair to ensure the proposal is closely tied to the research agenda of the Alliance.

Alliance Scholar Award recipients will receive a two-year, non-renewable cancer research grant of $40,000 direct costs per year, plus 10 percent indirect costs each year for two years. Successful applicants will be announced at the 2015 Alliance Fall Group Meeting, held in Chicago November 4-8. Funding will begin approximately January 1, 2016.

Applications due June 15, 2015

 Children's Leukemia Research Association, Inc. (CLRA): Research Grants | Applications due June 30, 2015

Children's Leukemia Research Association, Inc. (CLRA): Research Grants

Each year, CLRA's Medical Advisory Committee, consisting of prominent internationally known and respected hematologists, reviews submitted research proposals from doctors nationwide. Using contributions, they fund research grants for doctors who are conducting the most promising research into leukemia, in the hopes of isolating the causes and finding a cure for this dread disease. Grants are limited to a maximum of $30,000 each.

Applications due June 30, 2015

 Lung Cancer Research Foundation (LCRF): Research Grants | Applications due July 1, 2015

Lung Cancer Research Foundation (LCRF): Research Grants

The Lung Cancer Research Foundation is proud to fund research that they believe will make major contributions toward better treatments, screening, and prevention of lung cancer. The maximum award is $75,000, for a one-year period.

LCRF has funded research in all of the following areas: Development of cutting-edge drugs; Identification of clinical applications for new lung cancer therapies; Identification of new biomarkers for treatment selection/resistance to therapy, prognosis, and early detection.

Support for investigators at all levels – from postdoctoral students to world leaders in the field of:

  • Psychosocial research into lung cancer
  • Prevention and early detection of lung cancer
  • Improved staging of lung cancer
  • Understanding of the pathways of lung cancer growth
  • Alternative/complementary therapy for lung

Applications due July 1, 2015

 The Hope Foundation: SWOG Early Exploration and Development (SEED) Fund | Applications due July 1, 2015

The Hope Foundation: SWOG Early Exploration and Development (SEED) Fund

SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. SWOG is a National Cancer Institute-supported network of more than 5,000 cancer researchers at more than 650 institutions in the U.S., Canada, and beyond. Additional educational and cancer research support is provided by SWOG's non-profit, philanthropic partner, The Hope Foundation. Awards are made from The Hope Foundation SEED Fund to encourage preliminary research that will potentially translate to future clinical trials or trial associated projects (translational medicine studies) within SWOG and the NCTN. These awards may assist investigators with projects that support the following types of studies: pre-clinical data, secondary data analysis from clinical trials, pilot and feasibility studies (including early stage clinical trials), small, self-contained research projects, or development of research methodology/technology. Any SWOG investigator eligible for NIH funding is encouraged to submit to this program. Individual projects may be funded for up to $50,000 (direct costs) and may be spent over a 1- or 2-year award period. Indirect costs are limited to a rate of 25%.

Applications due July 1, 2015

 Free to Breathe: Accelerate Clinical Trials Grant | Applications due July 17, 2015

Free to Breathe: Accelerate Clinical Trials Grant

Free to Breathe's goal is to fund pilot research projects that will investigate novel strategies to improve accrual of lung cancer patients to therapeutic cancer clinical trials by at least 50% within a defined healthcare facility, system or community. Project aims must have specific strategies focused on increasing accrual to lung cancer trials. Proposals must have a clear vision about how the pilot project, if successful, can be an expanded to other institutions for validation of the intervention or strategy. The intent of Free to Breathe is to fund projects that will be reproducible and implementable to a wider community, including other cancers. For 2015, Free to Breathe expects to support one to two awards of up to $100,000, including a maximum of 8% ($8,000) indirect costs. Grants will be paid over 2 years at $50,000 per year. The second year payments will be contingent on receipt and approval of written progress reports. Anticipated funding start date is November 1, 2015. The Free to Breathe Research Grant is to be used primarily for project support. No more than 20% of the requested budget may be used for salary and fringe benefits for the principal investigator(s). The Grant is not designed to supplement an existing salary of the principal investigator.

Applications due July 17, 2015

Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53226
(414) 955-8296
Directions & Maps
© 2015

Page Updated 05/29/2015
Top